These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 29102703)

  • 21. Influence of variation in molar ratio on co-amorphous drug-amino acid systems.
    Jensen KT; Larsen FH; Löbmann K; Rades T; Grohganz H
    Eur J Pharm Biopharm; 2016 Oct; 107():32-9. PubMed ID: 27368747
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dissolution changes in drug-amino acid/biotin co-amorphous systems: Decreased/increased dissolution during storage without recrystallization.
    Zou Z; Huang Q; Li X; Liu X; Yin L; Zhao Y; Liang G; Wu W
    Eur J Pharm Sci; 2023 Sep; 188():106526. PubMed ID: 37442486
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Performance comparison between crystalline and co-amorphous salts of indomethacin-lysine.
    Kasten G; Nouri K; Grohganz H; Rades T; Löbmann K
    Int J Pharm; 2017 Nov; 533(1):138-144. PubMed ID: 28947246
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Preparation and characterization of amorphous ciprofloxacin-amino acid salts.
    Mesallati H; Conroy D; Hudson S; Tajber L
    Eur J Pharm Biopharm; 2017 Dec; 121():73-89. PubMed ID: 28919470
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Co-amorphous Drug Delivery Systems: a Review of Physical Stability, In Vitro and In Vivo Performance.
    Shi Q; Wang Y; Moinuddin SM; Feng X; Ahsan F
    AAPS PharmSciTech; 2022 Sep; 23(7):259. PubMed ID: 36123515
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sinapic Acid Co-Amorphous Systems with Amino Acids for Improved Solubility and Antioxidant Activity.
    Garbiec E; Rosiak N; Tykarska E; Zalewski P; Cielecka-Piontek J
    Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982605
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Formulation of co-amorphous systems from naproxen and naproxen sodium and in situ monitoring of physicochemical state changes during dissolution testing by Raman spectroscopy.
    Ueda H; Peter Bøtker J; Edinger M; Löbmann K; Grohganz H; Müllertz A; Rades T; Østergaard J
    Int J Pharm; 2020 Sep; 587():119662. PubMed ID: 32682958
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Co-Amorphous Formulations of Furosemide with Arginine and P-Glycoprotein Inhibitor Drugs.
    Ruponen M; Kettunen K; Santiago Pires M; Laitinen R
    Pharmaceutics; 2021 Jan; 13(2):. PubMed ID: 33514009
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dissolution properties of co-amorphous drug-amino acid formulations in buffer and biorelevant media.
    Heikkinen AT; DeClerck L; Löbmann K; Grohganz H; Rades T; Laitinen R
    Pharmazie; 2015 Jul; 70(7):452-7. PubMed ID: 26373205
    [TBL] [Abstract][Full Text] [Related]  

  • 30. An investigation into the influence of counterion on the properties of some amorphous organic salts.
    Towler CS; Li T; Wikström H; Remick DM; Sanchez-Felix MV; Taylor LS
    Mol Pharm; 2008; 5(6):946-55. PubMed ID: 19434850
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Emerging trends in the stabilization of amorphous drugs.
    Laitinen R; Löbmann K; Strachan CJ; Grohganz H; Rades T
    Int J Pharm; 2013 Aug; 453(1):65-79. PubMed ID: 22569230
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Recent advances in co-amorphous drug formulations.
    Dengale SJ; Grohganz H; Rades T; Löbmann K
    Adv Drug Deliv Rev; 2016 May; 100():116-25. PubMed ID: 26805787
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The use of molecular descriptors in the development of co-amorphous formulations.
    Meng-Lund H; Kasten G; Jensen KT; Poso A; Pantsar T; Rades T; Rantanen J; Grohganz H
    Eur J Pharm Sci; 2018 Jul; 119():31-38. PubMed ID: 29649569
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Considerations for the selection of co-formers in the preparation of co-amorphous formulations.
    Yarlagadda DL; Sai Krishna Anand V; Nair AR; Navya Sree KS; Dengale SJ; Bhat K
    Int J Pharm; 2021 Jun; 602():120649. PubMed ID: 33915186
    [TBL] [Abstract][Full Text] [Related]  

  • 35. smartPearls - Novel physically stable amorphous delivery system for poorly soluble dermal actives.
    Müller RH; Hespeler D; Jin N; Pyo SM
    Int J Pharm; 2019 Jan; 555():314-321. PubMed ID: 30439490
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Development of a screening method for co-amorphous formulations of drugs and amino acids.
    Kasten G; Grohganz H; Rades T; Löbmann K
    Eur J Pharm Sci; 2016 Dec; 95():28-35. PubMed ID: 27531419
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Manufacture and performance evaluation of a stable amorphous complex of an acidic drug molecule and Neusilin.
    Maclean J; Medina C; Daurio D; Alvarez-Nunez F; Jona J; Munson E; Nagapudi K
    J Pharm Sci; 2011 Aug; 100(8):3332-3344. PubMed ID: 21520086
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Salt formation to improve drug solubility.
    Serajuddin AT
    Adv Drug Deliv Rev; 2007 Jul; 59(7):603-16. PubMed ID: 17619064
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sulfonic Acid Derivatives in the Production of Stable Co-Amorphous Systems for Solubility Enhancement.
    da Costa NF; Santos IA; Fernandes AI; Pinto JF
    J Pharm Sci; 2022 Dec; 111(12):3327-3339. PubMed ID: 36007560
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Improving co-amorphous drug formulations by the addition of the highly water soluble amino Acid, proline.
    Jensen KT; Löbmann K; Rades T; Grohganz H
    Pharmaceutics; 2014 Jul; 6(3):416-35. PubMed ID: 25025400
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.